c-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway

Oncology Research

Volumn 20, Issue 4, 2012, Pages 149-156

  Han, Gang ^a   Wang, Yan ^a   Bi, Wenzhi ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

C Myc; Invasion; Mek erk pathway; Osteosarcoma

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; BETA TUBULIN; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN;

ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; INHIBITION KINETICS; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

EID: 84871899404     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504012X13522227232237     Document Type: Article

References (28)

1. Ottaviani, G.; Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat. Res. 152:3-13; 2009.
2. Provisor, A. J.; Ettinger, L. J.; Nachman, J. B.; Krailo, M. D.; Makley, J. T.; Yunis, E. J.; Huvos, A. G.; Betcher, D. L.; Baum, E. S.; Kisker, C. T.; Miser, J. S. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J. Clin. Oncol. 15:76-84; 1997.
3. Ferguson, W. S.; Goorin, A. M. Current treatment of osteosarcoma. Cancer Invest. 19:292-315; 2001.
4. Dang, C. V.; O'Donnell, K. A.; Zeller, K. I.; Nguyen, T.; Osthus, R. C.; Li, F. The c-Myc target gene network. Semin. Cancer Biol. 16:253-264; 2006.
5. Land, H.; Parada, L. F.; Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596-602; 1983.
6. Dang, C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19:1-11; 1999.
7. Wang, Y.; Wu, M. C.; Sham, J. S.; Zhang, W.; Wu, W. Q.; Guan, X. Y. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 95:2346-2352; 2002.
8. Oster, S. K.; Ho, C. S.; Soucie, E. L.; Penn, L. Z. The myc oncogene: Marvelously complex. Adv. Cancer Res. 84:81-154; 2002.
9. Shimizu, T.; Ishikawa, T.; Sugihara, E.; Kuninaka, S.; Miyamoto, T.; Mabuchi, Y.; Matsuzaki, Y.; Tsunoda, T.; Miya, F.; Morioka, H.; Nakayama, R.; Kobayashi, E.; Toyama, Y.; Kawai, A.; Ichikawa, H.; Hasegawa, T.; Okada, S.; Ito, T.; Ikeda, Y.; Suda, T.; Saya, H. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 29:5687-5699; 2010.
10. Xie, X. K.; Yang, D. S.; Ye, Z. M.; Tao, H. M. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines. Chemotherapy 55:433-440; 2009.
11. Hattinger, C. M.; Stoico, G.; Michelacci, F.; Pasello, M.; Scionti, I.; Remondini, D.; Castellani, G. C.; Fanelli, M.; Scotlandi, K.; Picci, P.; Serra, M. Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 48:289-309; 2009.
12. Scionti, I.; Michelacci, F.; Pasello, M.; Hattinger, C. M.; Alberghini, M.; Manara, M. C.; Bacci, G.; Ferrari, S.; Scotlandi, K.; Picci, P.; Serra, M. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann. Oncol. 19:1500-1508; 2008.
13. Robanus-Maandag, E. C.; Bosch, C. A.; Kristel, P. M.; Hart, A. A.; Faneyte, I. F.; Nederlof, P. M.; Peterse, J. L.; van de Vijver, M. J. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J. Pathol. 201:75-82; 2003.
14. Liu, B.; Wang, G.; Yang, J.; Pan, X.; Yang, Z.; Zang, L. Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes. PLoS One 6:e21416; 2011.
15. Meier, F.; Schittek, B.; Busch, S.; Garbe, C.; Smalley, K.; Satyamoorthy, K.; Li, G.; Herlyn, M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. 10:2986-3001; 2005.
16. McCubrey, J. A.; Steelman, L. S.; Abrams, S. L.; Lee, J. T.; Chang, F.; Bertrand, F. E.; Navolanic, P. M.; Terrian, D. M.; Franklin, R. A.; D'Assoro, A. B.; Salisbury, J. L.; Mazzarino, M. C.; Stivala, F.; Libra, M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46:249-279; 2006.
17. Cho, H. J.; Lee, T. S.; Park, J. B.; Park, K. K.; Choe, J. Y.; Sin, D. I.; Park, Y. Y.; Moon, Y. S.; Lee, K. G.; Yeo, J. H.; Han, S. M.; Cho, Y. S.; Choi, M. R.; Park, N. G.; Lee, Y. S.; Chang, Y. C. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J. Biochem. Mol. Biol. 40:1069-1076; 2007.
18. Steelman, L. S.; Abrams, S. L.; Whelan, J.; Bertrand, F. E.; Ludwig, D. E.; Basecke, J.; Libra, M.; Stivala, F.; Milella, M.; Tafuri, A.; Lunghi, P.; Bonati, A.; Martelli, A. M.; McCubrey, J. A. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22:686-707; 2008.
19. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R. A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773:1263-1284; 2007.
20. Cheng, J. C.; Chou, C. H.; Kuo, M. L.; Hsieh, C. Y. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25:7009-7018; 2006.
21. Itoh, Y.; Nagase, H. Matrix metalloproteinases in cancer. Essays Biochem. 38:21-36; 2002.
22. Ramer, R.; Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl. Cancer Inst. 100:59-69; 2008.
23. Chuan, Y. C.; Iglesias-Gato, D.; Fernandez-Perez, L.; Cedazo-Minguez, A.; Pang, S. T.; Norstedt, G.; Pousette, A.; Flores-Morales, A. Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene 29:1531-1542; 2010.
24. Cho, K. B.; Cho, M. K.; Lee, W. Y.; Kang, K. W. Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett. 293:230-239; 2010.
25. Alfano, D.; Votta, G.; Schulze, A.; Downward, J.; Caputi, M.; Stoppelli, M. P.; Iaccarino, I. Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor. Mol. Cell. Biol. 30:1838-1851; 2010.
26. Zhuang, S.; Yan, Y.; Daubert, R. A.; Han, J.; Schnellmann, R. G. ERK promotes hydrogen peroxide-induced apoptosis through caspase-3 activation and inhibition of Akt in renal epithelial cells. Am. J. Physiol. Renal. Physiol. 292:F440-447; 2007.
27. Biroccio, A.; Benassi, B.; Amodei, S.; Gabellini, C.; Del Bufalo, D.; Zupi, G. c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol. Pharmacol. 60:174-182; 2001.
28. Vafa, O.; Wade, M.; Kern, S.; Beeche, M.; Pandita, T. K.; Hampton, G. M.; Wahl, G. M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell 9:1031-1044; 2002.